Hepatocellular Carcinoma Clinical Trial
Official title:
Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial
This prospective, multicenter, randomized, controlled study aims to evaluate the efficacy and
safety of sorafenib combined with transarterial chemoembolization (TACE) in advanced
hepatocellular carcinoma (HCC) patients compared with sorafenib alone, and to determine the
prognostic factors that influence the survival.
Data on the efficacy and safety of sorafenib in combination with TACE in patients with
advanced HCC are lacking. Because in western countries, advanced HCC is considered as a
contraindication for TACE treatment. However, clinical practice patterns differ markedly
between Asia and western countries: in Asia TACE is performed in selected advanced HCC
patients. We consider sorafenib combined with TACE could achieve better survival benefit than
sorafenib alone in selected advanced HCC patients.
PRIMARY OBJECTIVE:
To compare the overall survival of selected advanced HCC patients treated with sorafenib
combined with TACE with sorafenib alone.
SECONDARY OBJECTIVES:
1. To compare the time to progression(TTP).
2. To compare the tumor response and disease control rate according to Response Evaluation
Criteria in Solid Tumors(RECIST), modified Response Evaluation Criteria in Solid
Tumors(mRECIST) and European Association of Liver Disease(EASL) criteria.
3. To compare the safety.
OTHER OBJECTIVES:
1. To explore the prognostic value of AFP response after treatment.
OUTLINE: This is a multicenter, phase 3, prospective, randomized, controlled trial. Patients
are stratified according to
1. ECOG ( 0 vs. 1)
2. Child-Pugh (A vs. B7)
3. Tumor burden
1. single vs. multiple lesions
2. tumor size (>8cm vs. ≤8cm)
3. vascular invasion (yes vs. no)
4. extrahepatic metastasis (yes vs. no)
4. Alpha fetoprotein(AFP)(≤ 200 ng/mL vs. > 200 ng/mL) Patients are randomized to 1 of 2
treatment arms.
ARM I: Patients receive two tablets of sorafenib (200 mg tablets) twice daily (each morning
and evening). Patients undergo the first conventional transarterial chemoembolization (TACE)
within 3-7 days after the first administration of sorafenib. The conventional TACE consists
of an injection containing a mixture of chemotherapeutic agents (doxorubicin) and lipiodol
followed by embolization with polyvinyl alcohol (PVA) or beads until complete stasis was
achieved in the tumor-feeding vessels. Tumor-feeding vessels should be selected/superselected
whenever possible. TACE will be repeated "on demand" depending on the radiological response.
ARM II: Patients receive two tablets of sorafenib (200 mg tablets) twice daily (each morning
and evening).
MAINTENANCE THERAPY: Standard follow-up evaluations include contrast-enhanced CT scan and
laboratory assessment. Laboratory assessment will be performed every 4 weeks. Radiological
follow-up (contrast-enhanced CT scan in liver and chest X-ray) will be performed during week
4 and week 8 after initiation of treatment and thereafter every 8 weeks.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04209491 -
Interest of the Intervention of a Nurse Coordinator in Complex Care Pathway
|
||
Completed |
NCT03963206 -
Cabozantinib toLERANCE Study in HepatoCellular Carcinoma (CLERANCE)
|
Phase 4 | |
Completed |
NCT03268499 -
TACE Emulsion Versus Suspension
|
Phase 2 | |
Recruiting |
NCT05263830 -
Glypican-3 as a Prognostic Factor in Patients With Hepatocellular Carcinoma Treated by Immunotherapy
|
||
Recruiting |
NCT05044676 -
Immune Cells as a New Biomarker of Response in Patients Treated by Immunotherapy for Advanced Hepatocellular Carcinoma
|
||
Recruiting |
NCT05095519 -
Hepatocellular Carcinoma Imaging Using PSMA PET/CT
|
Phase 2 | |
Recruiting |
NCT05497531 -
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
|
N/A | |
Completed |
NCT05068193 -
A Clinical Trial to Compare the Pharmacokinetics and Bioequivalence of "BR2008" With "BR2008-1" in Healthy Volunteers
|
Phase 1 | |
Active, not recruiting |
NCT03781934 -
A Study to Evaluate MIV-818 in Patients With Liver Cancer Manifestations
|
Phase 1/Phase 2 | |
Terminated |
NCT03655613 -
APL-501 or Nivolumab in Combination With APL-101 in Locally Advanced or Metastatic HCC and RCC
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04242199 -
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors
|
Phase 1 | |
Completed |
NCT04401800 -
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
|
Phase 2 | |
Withdrawn |
NCT05418387 -
A Social Support Intervention to Improve Treatment Among Hispanic Kidney and Liver Cancer Patients in Arizona
|
N/A | |
Active, not recruiting |
NCT04039607 -
A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma
|
Phase 3 | |
Terminated |
NCT03970616 -
A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT06239155 -
A Phase I/II Study of AST-3424 in Subjects With Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT03642561 -
Evaluation the Treatment Outcome for RFA in Patients With BCLC Stage B HCC in Comparison With TACE
|
Phase 2/Phase 3 | |
Recruiting |
NCT04118114 -
Phase II Study of PRL3-ZUMAB in Advanced Solid Tumors
|
Phase 2 | |
Completed |
NCT03222076 -
Nivolumab With or Without Ipilimumab in Treating Patients With Resectable Liver Cancer
|
Phase 2 |